MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction
The aim of this study was to correlate the pre-procedural magnetic-resonance-imaging-based hepatic fat fraction (hFF) with the degree of hypertrophy after portal vein embolization (PVE) in patients with colorectal cancer liver metastases (CRCLM). Between 2011 November and 2020 February, 68 patients...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/9/2003 |
| _version_ | 1797535017706979328 |
|---|---|
| author | Lea Hitpass Iakovos Amygdalos Paul Sieben Vanessa Raaff Sven Lang Philipp Bruners Christiane K. Kuhl Alexandra Barabasch |
| author_facet | Lea Hitpass Iakovos Amygdalos Paul Sieben Vanessa Raaff Sven Lang Philipp Bruners Christiane K. Kuhl Alexandra Barabasch |
| author_sort | Lea Hitpass |
| collection | DOAJ |
| description | The aim of this study was to correlate the pre-procedural magnetic-resonance-imaging-based hepatic fat fraction (hFF) with the degree of hypertrophy after portal vein embolization (PVE) in patients with colorectal cancer liver metastases (CRCLM). Between 2011 November and 2020 February, 68 patients with CRCLM underwent magnetic resonance imaging (MRI; 1.5 Tesla) of the liver before PVE. Using T1w chemical shift imaging (DUAL FFE), the patients were categorized as having a normal (<5%) or an elevated (>5%) hFF. The correlation of hFF, age, gender, initial tumor mass, history of chemotherapy, degree of liver hypertrophy, and kinetic growth rate after PVE was investigated using multiple regression analysis and Spearman’s test. A normal hFF was found in 43/68 patients (63%), whereas 25/68 (37%) patients had an elevated hFF. The mean hypertrophy and kinetic growth rates in patients with normal vs. elevated hFF were 24 ± 31% vs. 28 ± 36% and 9 ± 9 % vs. 8 ± 10% (<i>p</i> > 0.05), respectively. Spearman’s test showed no correlation between hFF and the degree of hypertrophy (R = −0.04). Multivariable analysis showed no correlation between hFF, history of chemotherapy, age, baseline tumor burden, or laterality of primary colorectal cancer, and only a poor inverse correlation between age and kinetic growth rate after PVE. An elevated hFF in a pre-procedural MRI does not correlate with the hypertrophy rate after PVE and should therefore not be used as a contraindication to the procedure in patients with CRCLM. |
| first_indexed | 2024-03-10T11:38:38Z |
| format | Article |
| id | doaj.art-76bb51c55be04527ab676b95a99d72ce |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T11:38:38Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-76bb51c55be04527ab676b95a99d72ce2023-11-21T18:39:38ZengMDPI AGJournal of Clinical Medicine2077-03832021-05-01109200310.3390/jcm10092003MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat FractionLea Hitpass0Iakovos Amygdalos1Paul Sieben2Vanessa Raaff3Sven Lang4Philipp Bruners5Christiane K. Kuhl6Alexandra Barabasch7Department of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Surgery and Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Surgery and Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyDepartment of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, GermanyThe aim of this study was to correlate the pre-procedural magnetic-resonance-imaging-based hepatic fat fraction (hFF) with the degree of hypertrophy after portal vein embolization (PVE) in patients with colorectal cancer liver metastases (CRCLM). Between 2011 November and 2020 February, 68 patients with CRCLM underwent magnetic resonance imaging (MRI; 1.5 Tesla) of the liver before PVE. Using T1w chemical shift imaging (DUAL FFE), the patients were categorized as having a normal (<5%) or an elevated (>5%) hFF. The correlation of hFF, age, gender, initial tumor mass, history of chemotherapy, degree of liver hypertrophy, and kinetic growth rate after PVE was investigated using multiple regression analysis and Spearman’s test. A normal hFF was found in 43/68 patients (63%), whereas 25/68 (37%) patients had an elevated hFF. The mean hypertrophy and kinetic growth rates in patients with normal vs. elevated hFF were 24 ± 31% vs. 28 ± 36% and 9 ± 9 % vs. 8 ± 10% (<i>p</i> > 0.05), respectively. Spearman’s test showed no correlation between hFF and the degree of hypertrophy (R = −0.04). Multivariable analysis showed no correlation between hFF, history of chemotherapy, age, baseline tumor burden, or laterality of primary colorectal cancer, and only a poor inverse correlation between age and kinetic growth rate after PVE. An elevated hFF in a pre-procedural MRI does not correlate with the hypertrophy rate after PVE and should therefore not be used as a contraindication to the procedure in patients with CRCLM.https://www.mdpi.com/2077-0383/10/9/2003magnetic resonance imagingliversteatosisembolizationhypertrophy |
| spellingShingle | Lea Hitpass Iakovos Amygdalos Paul Sieben Vanessa Raaff Sven Lang Philipp Bruners Christiane K. Kuhl Alexandra Barabasch MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction Journal of Clinical Medicine magnetic resonance imaging liver steatosis embolization hypertrophy |
| title | MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction |
| title_full | MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction |
| title_fullStr | MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction |
| title_full_unstemmed | MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction |
| title_short | MRI-Based Quantitation of Hepatic Steatosis Does Not Predict Hypertrophy Rate after Portal Vein Embolization in Patients with Colorectal Liver Metastasis and Normal to Moderately Elevated Fat Fraction |
| title_sort | mri based quantitation of hepatic steatosis does not predict hypertrophy rate after portal vein embolization in patients with colorectal liver metastasis and normal to moderately elevated fat fraction |
| topic | magnetic resonance imaging liver steatosis embolization hypertrophy |
| url | https://www.mdpi.com/2077-0383/10/9/2003 |
| work_keys_str_mv | AT leahitpass mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT iakovosamygdalos mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT paulsieben mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT vanessaraaff mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT svenlang mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT philippbruners mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT christianekkuhl mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction AT alexandrabarabasch mribasedquantitationofhepaticsteatosisdoesnotpredicthypertrophyrateafterportalveinembolizationinpatientswithcolorectallivermetastasisandnormaltomoderatelyelevatedfatfraction |